Freenome, Inc. Common stock
Freenome, Inc. Common stock
Your view on FRNM
Overview
What the company does, where it operates, and who runs it.
About Freenome, Inc. Common stock
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Aaron Elliott
- Headquarters
- 3300 Marina Boulevard, Brisbane, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Aaron Elliott
- Headquarters
- 3300 Marina Boulevard, Brisbane, CA, US
Perceptive Capital Solutions Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Joseph Eric Edelman, Adam Leo Stone, and Michael R.
Altman on March 22, 2024 and is headquartered in New York, NY.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Freenome, Inc. Common stock from FRC's valuation model, read against the market price. FRNM last traded at $10.61; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Freenome, Inc. Common stock. Starting points for Freenome, Inc. Common stock: beta 0.35 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Freenome, Inc. Common stock. Freenome, Inc. Common stock does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Freenome, Inc. Common stock. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$17.00
Median
$17.50
High
$21.00
Average target · 4 new targets in the last 3 months, average $18.25
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Freenome, Inc. Common stock. Freenome, Inc. Common stock has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Freenome, Inc. Common stock valued side by side against its closest peers. Freenome, Inc. Common stock is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Freenome, Inc. Common stock executives and directors. Shares of Freenome, Inc. Common stock have traded between $9.95 and $14.47 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Freenome, Inc. Common stock. Coverage tracks Freenome, Inc. Common stock within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Freenome, Inc. Common stock.